Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Polatuzumab vedotin, marketed under the trade name POLIVY(®), is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E) to B cells, resulting in anti-cancer activity against B-cell malignancies. In 2019, polatuzumab vedotin in comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Dere, Randall C., Beardsley, Richard L., Lu, Dan, Lu, Tong, Ku, Grace H-W., Man, Gabriel, Nguyen, Van, Kaur, Surinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090561/
https://www.ncbi.nlm.nih.gov/pubmed/37063860
http://dx.doi.org/10.3389/fimmu.2023.1119510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090561/
https://www.ncbi.nlm.nih.gov/pubmed/37063860
http://dx.doi.org/10.3389/fimmu.2023.1119510

Ejemplares similares